SCHEMBL19174255

SCHEMBL19174255

CCCCCC/C(=N/S(N)(=O)=O)NC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.39
CES2 O00748 3/20 0.38
CES1 P23141 3/20 0.38
HSP90AA1 P07900 1/20 0.37
GPR84 Q9NQS5 7/20 0.36
PPARG P37231 7/20 0.36
PPARD Q03181 7/20 0.36
PPARA Q07869 7/20 0.36
HDAC11 Q96DB2 5/20 0.36
TSHR P16473 4/20 0.36
PTPN1 P18031 3/20 0.36
ALDH1A1 P00352 2/20 0.36
TLR2 O60603 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
FABP4 P15090 2/20 0.36
SLC22A6 Q4U2R8 1/20 0.36
SLC22A8 Q8TCC7 1/20 0.36
MEN1 O00255 1/20 0.36
ESR1 P03372 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18665148 0.98 CA1 (0.36) FAAHCES2CES1HSP90AA1GPR84
SCHEMBL13670698 0.85 CTSD (0.32) CA1CA2CA9
SCHEMBL18665143 0.73 SPHK2 (0.40) FAAHCES2CES1GPR84PPARG
SCHEMBL3387041 0.72 CES2 (0.41) FAAHCES2CES1HSP90AA1GPR84
SCHEMBL3387043 0.72 CES2 (0.41) FAAHCES2CES1HSP90AA1GPR84
SCHEMBL22645876 0.71 EPHX1 (0.42) PPARAMEN1KMT2ACA1CA2
SCHEMBL19771875 0.71 CES2 (0.38) CES2CES1GPR84PPARGPPARD
SCHEMBL14137675 0.70 CES2 (0.39) FAAHCES2CES1HSP90AA1GPR84
SCHEMBL18665165 0.69 ALDH1A1 (0.36) CES2CES1GPR84PPARGPPARD
SCHEMBL22642604 0.68 SPHK2 (0.34) FAAHCES2CES1HSP90AA1GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021022173-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF RNA INTERFERENCE AGENTS TO IMMUNE CELLS MODERNATX, INC. (US) 2021-02-04 WO disclosed
US-10857105-B2 Compounds and compositions for intracellular delivery of therapeutic agents MordernaTX, Inc. (US) 2020-12-08 US disclosed
US-20190314292-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2019-10-17 US disclosed
WO-2019152557-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS MODERNATX, INC. (US) 2019-08-08 WO disclosed
US-20170210698-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2017-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170210698-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS LNPK, PLTP, PLIN3 FAAH 3137/4885CES2 2064/4885CES1 1183/4885
US-10857105-B2 Compounds and compositions for intracellular delivery of therapeutic agents LNPK, PLTP, PLIN3 FAAH 3137/4885CES2 2064/4885CES1 1183/4885
US-20190314292-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS LNPK, PLTP, PLIN3 FAAH 3137/4885CES2 2064/4885CES1 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.